Amprion to Expand Diagnostic Testing for Neurodegenerative Disorders with Investment from Decathlon Capital Partners
Amprion, Inc. is expanding its diagnostic testing for neurodegenerative disorders with an investment from Decathlon Capital Partners. The funding will support growth without equity dilution or loss of management control.
San Diego, Calif. – Amprion, Inc. has secured an investment agreement with Decathlon Capital Partners to expand its diagnostic testing capabilities for neurodegenerative disorders. The company utilizes seed-amplification testing to advance the diagnosis of these conditions.
The agreement provides Amprion with flexible financing that reportedly avoids equity dilution and preserves management control. This structure is intended to support the company's planned growth and development in its diagnostic services sector.
Amprion's technologies aim to improve the early and accurate diagnosis of diseases such as Alzheimer's and Parkinson's. The investment is expected to facilitate further research and development, as well as increased capacity to meet demand for reliable diagnostic tools.
While specific financial terms of the investment were not disclosed, Amprion stated the goal is to enhance the availability of its diagnostic services globally, ultimately improving patient care through faster and more precise diagnoses.